US Stock MarketDetailed Quotes
XENE Xenon Pharmaceuticals
- 43.750
- +0.750+1.74%
Close May 3 16:00 ET
- 43.930
- +0.180+0.41%
Post 17:30 ET
3.30BMarket Cap-16025P/E (TTM)
43.790High42.840Low252.22KVolume43.580Open43.000Pre Close10.98MTurnover0.36%Turnover RatioLossP/E (Static)75.46MShares50.99052wk High3.56P/B3.04BFloat Cap27.98552wk Low--Dividend TTM69.59MShs Float50.990Historical High--Div YieldTTM2.21%Amplitude2.100Historical Low43.524Avg Price1Lot Size
Xenon Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -47.65%-145.33M | -8.35%-35.47M | -38.91%-42.23M | -96.95%-33.22M | -86.73%-34.41M | -41.62%-98.43M | -58.05%-32.73M | -102.59%-30.4M | -28.99%-16.87M | 11.01%-18.43M |
| Net income from continuing operations | -45.48%-182.39M | -19.65%-44.74M | -30.45%-48.46M | -52.32%-47.46M | -112.14%-41.73M | -58.94%-125.37M | -46.28%-37.4M | -140.53%-37.15M | -40.93%-31.16M | -24.78%-19.67M |
| Operating gains losses | -123.45%-640K | 115.59%113K | -110.16%-301K | -170.50%-447K | 96.48%-5K | 734.56%2.73M | -484.68%-725K | 573.18%2.96M | 194.88%634K | 30.39%-142K |
| Depreciation and amortization | 118.04%3.54M | 65.24%851K | 384.36%1.73M | 60.53%602K | -5.85%354K | 79.25%1.62M | 90.74%515K | 71.29%358K | 62.34%375K | 91.84%376K |
| Deferred tax | -563.64%-292K | -4,100.00%-200K | 23.15%-156K | -115.38%-224K | 11.63%288K | -175.86%-44K | -98.55%5K | 23.97%-203K | -246.67%-104K | 2,766.67%258K |
| Change In working capital | 933.58%5.64M | -148.97%-522K | -37.13%-3.3M | 0.04%6.89M | 141.17%2.56M | 74.46%-676K | 5.54%1.07M | 6.31%-2.41M | 16.88%6.89M | 10.85%-6.23M |
| -Change in receivables | -92.60%130K | -119.41%-294K | 2,114.29%155K | -88.97%43K | 245.81%226K | 482.79%1.76M | 214.97%1.52M | 102.11%7K | -85.17%390K | 95.21%-155K |
| -Change in prepaid assets | 115.00%1.57M | 60.89%-2.53M | 97.85%-96K | 78.34%1.27M | 1,177.57%2.93M | -591.83%-10.5M | -529.70%-6.47M | -3,068.09%-4.47M | 286.41%711K | 48.97%-272K |
| -Change in payables and accrued expense | -51.24%3.93M | -61.76%2.3M | -263.36%-3.36M | -3.58%5.58M | 89.76%-594K | 171.36%8.06M | 60.14%6.02M | 261.68%2.06M | 56.56%5.79M | -80.49%-5.8M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -47.65%-145.33M | -8.35%-35.47M | -38.91%-42.23M | -96.95%-33.22M | -86.73%-34.41M | -41.62%-98.43M | -58.05%-32.73M | -102.59%-30.4M | -28.99%-16.87M | 11.01%-18.43M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 60.42%-117.17M | -1,572.31%-239.73M | 120.52%48.03M | 2,018.60%27.9M | 195.36%46.62M | -19.95%-296M | 93.35%-14.34M | -1,603.03%-234.1M | -83.92%1.32M | 11.28%-48.89M |
| Net PPE purchase and sale | -94.09%-5.62M | 95.55%-78K | -210.88%-1.2M | -292.10%-2.13M | -940.57%-2.21M | -41.17%-2.89M | -240.86%-1.75M | -73.09%-386K | 40.15%-544K | 47.52%-212K |
| Net investment purchase and sale | 61.94%-111.55M | -1,804.54%-239.65M | 121.07%49.23M | 1,513.92%30.04M | 200.31%48.83M | -19.77%-293.11M | 94.15%-12.58M | -1,579.37%-233.71M | -79.55%1.86M | 11.01%-48.68M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 60.42%-117.17M | -1,572.31%-239.73M | 120.52%48.03M | 2,018.60%27.9M | 195.36%46.62M | -19.95%-296M | 93.35%-14.34M | -1,603.03%-234.1M | -83.92%1.32M | 11.28%-48.89M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 26.95%353.52M | 5,400,133.33%324.01M | 4,121.46%29.51M | 0 | 0 | -37.78%278.47M | -100.00%6K | -85.31%699K | 243,044.14%269.89M | -93.37%7.88M |
| Net common stock issuance | 27.26%353.49M | --323.98M | --29.51M | --0 | --0 | -37.90%277.77M | --0 | --0 | --269.89M | -93.36%7.88M |
| Proceeds from stock option exercised by employees | -95.04%35K | 483.33%35K | ---- | ---- | ---- | 171.15%705K | -60.00%6K | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 26.95%353.52M | 5,400,133.33%324.01M | 4,121.46%29.51M | --0 | --0 | -37.78%278.47M | -100.00%6K | -85.31%699K | 243,044.14%269.89M | -93.37%7.88M |
| Net cash flow | ||||||||||
| Beginning cash position | -67.42%57.24M | -3.78%99.57M | -82.55%64.55M | -40.35%69.51M | -67.42%57.24M | 290.34%175.69M | 17.86%103.49M | 346.14%369.99M | 32.46%116.54M | 290.34%175.69M |
| Current changes in cash | 178.50%91.03M | 203.74%48.82M | 113.39%35.31M | -102.09%-5.32M | 120.54%12.21M | -188.34%-115.96M | -153.59%-47.06M | -5,053.06%-263.8M | 5,427.59%254.34M | -238.53%-59.44M |
| Effect of exchange rate changes | 115.14%376K | -69.78%246K | 89.33%-288K | 140.20%359K | -79.86%59K | -319.59%-2.48M | 1,079.71%814K | -503.58%-2.7M | -217.79%-893K | 337.31%293K |
| End cash Position | 159.67%148.64M | 159.67%148.64M | -3.78%99.57M | -82.55%64.55M | -40.35%69.51M | -67.42%57.24M | -67.42%57.24M | 17.86%103.49M | 346.14%369.99M | 32.46%116.54M |
| Free cash flow | -48.97%-150.94M | -3.07%-35.54M | -41.06%-43.43M | -103.04%-35.35M | -96.44%-36.62M | -41.61%-101.32M | -62.48%-34.48M | -102.15%-30.79M | -24.50%-17.41M | 11.71%-18.64M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg